{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:01:18Z","timestamp":1784757678806,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"DOI":"10.7759\/cureus.113169","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:10:03Z","timestamp":1784754603000},"source":"Crossref","is-referenced-by-count":0,"title":["When Prostate Cancer Mimics Multiple Myeloma: Diffuse Bone Marrow Infiltration Revealing Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation"],"prefix":"10.7759","author":[{"given":"Latifa","family":"Lamine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaymae","family":"Senoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Nadif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soundous","family":"Bennour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Mokfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoufal N","family":"Berrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichrak","family":"Bouhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"lazrak","family":"Meryam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Boutaagount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Maskrout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf L","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, et al.. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000, 31:578-83. 10.1053\/hp.2000.6698","journal-title":"Hum Pathol"},{"key":"ref4","article-title":"Bone marrow metastasis by an occult prostatic adenocarcinoma mimicking essential thrombocythaemia","volume":"3","author":"Noor S","year":"2024","unstructured":"Noor S, Haidary AM, Hanifi AN, et al.. Bone marrow metastasis by an occult prostatic adenocarcinoma mimicking essential thrombocythaemia. Int J Med Case Rep Med Res. 2024, 3:","journal-title":"Int J Med Case Rep Med Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2402","article-title":"Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: a diagnostic pitfall","volume":"8","author":"Yigit N","year":"2014","unstructured":"Yigit N, Geyer JT. Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: a diagnostic pitfall. Can Urol Assoc J. 2014, 8:941-3. 10.5489\/cuaj.2402","journal-title":"Can Urol Assoc J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran H","year":"2012","unstructured":"Beltran H, Tagawa ST, Park K, et al.. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012, 30:386-9. 10.1200\/JCO.2011.41.5166","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio AM","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, et al.. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013, 19:3621-30. 10.1158\/1078-0432.CCR-12-3791","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis - a systematic review and pooled analysis","volume":"32","author":"Wang HT","year":"2014","unstructured":"Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis - a systematic review and pooled analysis. J Clin Oncol. 2014, 32:3383-90. 10.1200\/JCO.2013.54.3553","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00060","article-title":"The many faces of neuroendocrine differentiation in prostate cancer progression","volume":"4","author":"Terry S","year":"2014","unstructured":"Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol. 2014, 4:10.3389\/fonc.2014.00060","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/his.14707","article-title":"Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series","volume":"81","author":"Gopalan A","year":"2022","unstructured":"Gopalan A, Al-Ahmadie H, Chen YB, et al.. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. Histopathology. 2022, 81:246-54. 10.1111\/his.14707","journal-title":"Histopathology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman MS","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al.. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020, 395:1208-16. 10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22831","article-title":"Utility of FDG-PET in clinical neuroendocrine prostate cancer","volume":"74","author":"Spratt DE","year":"2014","unstructured":"Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR. Utility of FDG-PET in clinical neuroendocrine prostate cancer. Prostate. 2014, 74:1153-9. 10.1002\/pros.22831","journal-title":"Prostate"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al.. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017, 377:352-60. 10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737-46. 10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12533","article-title":"International Society of Urological Pathology (ISUP) grading of prostate cancer - an ISUP consensus on contemporary grading","volume":"124","author":"Egevad L","year":"2016","unstructured":"Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - an ISUP consensus on contemporary grading. APMIS. 2016, 124:433-5. 10.1111\/apm.12533","journal-title":"APMIS"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn PG","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, et al.. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019, 20:1432-43. 10.1016\/S1470-2045(19)30408-5","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512761-when-prostate-cancer-mimics-multiple-myeloma-diffuse-bone-marrow-infiltration-revealing-metastatic-prostate-adenocarcinoma-with-neuroendocrine-differentiation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:10:04Z","timestamp":1784754604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512761-when-prostate-cancer-mimics-multiple-myeloma-diffuse-bone-marrow-infiltration-revealing-metastatic-prostate-adenocarcinoma-with-neuroendocrine-differentiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113169","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}